<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1011368</article-id><article-id pub-id-type="publisher-id">ACM-38480</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201100000_18215112.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  新型冠状病毒(SARS-CoV-2)与严重急性呼吸综合征冠状病毒(SARS-CoV)研究对比
  The Comparison of SARS-CoV-2 and SARS-CoV
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>超</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>魏</surname><given-names>玉娇</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>宏稷</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>浩</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>超</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>许</surname><given-names>丰强</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>马</surname><given-names>瑞霞</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>安</surname><given-names>毅</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院心内科，山东 青岛</addr-line></aff><aff id="aff3"><addr-line>青岛大学附属医院肾病科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>11</month><year>2020</year></pub-date><volume>10</volume><issue>11</issue><fpage>2439</fpage><lpage>2443</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    2019年末我国武汉爆发了自2003年的SARS-CoV和2012年的中东呼吸综合症(MERS)以来又一次冠状病毒大规模爆发流行。截至2020年10月09日20时，世界卫生组织(World Health Organization, WHO)数据显示海外累计确诊病例36,725,069例，死亡病例1,062,153例，中国确诊人数达到了91,264例。此次疫情的严重性自然引起国人联想到2003年爆发的SARS病毒。且最新研究认为SARS-CoV-2是SARS-CoV的姊妹病毒，具有高度的同源性。因此我们将围绕SARS-CoV-2和SARS-CoV之间的联系以及SARS-CoV-2的最新诊疗方案进行简要综述。
    At the end of 2019, another large-scale outbreak of coronavirus broke out in Wuhan since SARS- CoV in 2003 and MERS in 2012. As of 20:00 on October 09, 2020, the World Health Organization (WHO) data showed that there were 36,725,069 confirmed cases and 1,062,153 deaths overseas, and the number of confirmed cases in China reached 91,264. The severity of the epidemic naturally caused people to associate with the outbreak of SARS virus in 2003. In addition, the latest studies suggest that SARS-CoV-2 is the sister virus of SARS CoV and has high homology. Therefore, we will focus on the relationship between SARS-CoV-2 and SARS-CoV, as well as the latest diagnosis and treatment of SARS-CoV-2. 
  
 
</p></abstract><kwd-group><kwd>新型冠状病毒(SARS-CoV-2)，严重急性呼吸综合征冠状病毒(SARS-CoV)，诊疗, SARS-CoV-2</kwd><kwd> SARS-CoV</kwd><kwd> Diagnosis and Treatment</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>2019年末我国武汉爆发了自2003年的SARS-CoV和2012年的中东呼吸综合症(MERS)以来又一次冠状病毒大规模爆发流行。截至2020年10月09日20时，世界卫生组织(World Health Organization, WHO)数据显示海外累计确诊病例36,725,069例，死亡病例1,062,153例，中国确诊人数达到了91,264例。此次疫情的严重性自然引起国人联想到2003年爆发的SARS病毒。且最新研究认为SARS-CoV-2是SARS-CoV的姊妹病毒，具有高度的同源性。因此我们将围绕SARS-CoV-2和SARS-CoV之间的联系以及SARS-CoV-2的最新诊疗方案进行简要综述。</p></sec><sec id="s2"><title>关键词</title><p>新型冠状病毒(SARS-CoV-2)，严重急性呼吸综合征冠状病毒(SARS-CoV)，诊疗</p></sec><sec id="s3"><title>The Comparison of SARS-CoV-2 and SARS-CoV<sup> </sup></title><p>Chao Chen<sup>1</sup>, Yujiao Wei<sup>2</sup>, Hongji Zhou<sup>1</sup>, Hao Zhang<sup>1</sup>, Chao Zhang<sup>1</sup>, Fengqiang Xu<sup>1</sup>, Ruixia Ma<sup>2</sup>, Yi An<sup>1*</sup></p><p><sup>1</sup>Division of Cardiology, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Division of Nephrology, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/2-1571632x5_hanspub.png" /></p><p>Received: Oct. 11<sup>th</sup>, 2020; accepted: Oct. 28<sup>th</sup>, 2020; published: Nov. 4<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/2-1571632x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>At the end of 2019, another large-scale outbreak of coronavirus broke out in Wuhan since SARS-CoV in 2003 and MERS in 2012. As of 20:00 on October 09, 2020, the World Health Organization (WHO) data showed that there were 36,725,069 confirmed cases and 1,062,153 deaths overseas, and the number of confirmed cases in China reached 91,264. The severity of the epidemic naturally caused people to associate with the outbreak of SARS virus in 2003. In addition, the latest studies suggest that SARS-CoV-2 is the sister virus of SARS CoV and has high homology. Therefore, we will focus on the relationship between SARS-CoV-2 and SARS-CoV, as well as the latest diagnosis and treatment of SARS-CoV-2.</p><p>Keywords:SARS-CoV-2, SARS-CoV, Diagnosis and Treatment</p><disp-formula id="hanspub.38480-formula5"><graphic xlink:href="//html.hanspub.org/file/2-1571632x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/2-1571632x8_hanspub.png" /> <img src="//html.hanspub.org/file/2-1571632x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>2019年末，武汉爆发了有史以来爆发流行范围最为广泛的冠状病毒感染，已然成为全球瞩目的公共卫生问题。面对这一突然爆发的疫情，我国迅速启动疫情防控机制，有效遏制了疫情在中国的传播，并为世界各地的疫情提供了积极援助。正是基于对此次导致疫情的病原体的基础研究以及逐渐完善的治疗方案，使得此次抗击疫情能够有条不紊的进行。现将目前最新的新冠病毒的基础研究以及中国经验进行阐述。</p></sec><sec id="s6"><title>2. 流行病学</title><p>急性呼吸综合征相关冠状病毒(SARSr-CoV)大多在可在宿主蝙蝠中发现 [<xref ref-type="bibr" rid="hanspub.38480-ref1">1</xref>]，石正丽等对SARS-CoV-2确诊病例中提取的全基因组序列发现，与蝙蝠冠状病毒具有96%的相似度，因此提出，蝙蝠可能是SARS-CoV-2的天然宿主 [<xref ref-type="bibr" rid="hanspub.38480-ref2">2</xref>]。而后在穿山甲体内发现的冠状病毒基因序列与确诊病例相似度达到了99%，由此认为穿山甲可能是SARS-CoV-2的中间宿主 [<xref ref-type="bibr" rid="hanspub.38480-ref3">3</xref>]。钟南山团队在大规模回顾性研究中发现，在1099例确诊患者中，1.18%有野生动物接触史，2.09%为医护一线人员，43.95%为武汉当地居民，71.80%的病例与武汉相关，只有26.00%患者与武汉无相关性 [<xref ref-type="bibr" rid="hanspub.38480-ref4">4</xref>]。据最新发布的新型冠状病毒肺炎诊疗方案(试行第六版)中表明，目前主要的传染源是新型冠状病毒感染的患者，主要传播途径是经呼吸道飞沫和密切接触传播，且在密闭场所、长时间暴露、高浓度的环境中存在经气溶胶传播的可能。人群具有普遍易感性 [<xref ref-type="bibr" rid="hanspub.38480-ref5">5</xref>]。2005年Lau等人在中国马蹄蝠中发现了与人类SARS-CoV相关的新型CoV，即SARS相关冠状病毒(SARSr-CoVs)，提示蝙蝠可能是SARS-CoV的自然宿主 [<xref ref-type="bibr" rid="hanspub.38480-ref6">6</xref>]。目前研究显示SARS-CoV-2与蝙蝠SARS样冠状病毒(bat-SL-CoVZC45)同源性达85%以上。SARS-CoV是一种高度传染性人畜共患性呼吸系统疾病，其主要传播方式是通过呼吸道飞沫和密切接触在人与人之间传播 [<xref ref-type="bibr" rid="hanspub.38480-ref7">7</xref>]。因此，从流行病层面看，SARS-CoV-2与SARS-CoV基本一致。</p></sec><sec id="s7"><title>3. 病原学</title><p>CoV为单股正链RNA病毒，基因组全长约30 kb，由5’-端非编码区、非结构蛋白ORF1a/b编码区、4种主要结构蛋白编码区以及3’-端非编码区组成 [<xref ref-type="bibr" rid="hanspub.38480-ref8">8</xref>]。Lu等从对9名确诊患者支气管肺泡灌洗液及其培养标本进行了基因测序，结果发现10条2019-nCoV基因组序列极其相似，且超过99.98%的序列同一性，而与SARS-CoV基因序列相似度为79%。此外，他们在同源建模中发现，2019-nCoV与SARS-CoV具有相似的受体结合域结构 [<xref ref-type="bibr" rid="hanspub.38480-ref9">9</xref>]。Shi等在基因测序中发现，2019-nCoV基因组序列几乎完全相同，且与SARS-CoV有79.5%的相似度 [<xref ref-type="bibr" rid="hanspub.38480-ref2">2</xref>]。因此，推断SARS-CoV-2与SARS-CoV属于同一物种，是一种新的变异类型，而不是一个新物种。</p></sec><sec id="s8"><title>4. 临床表现</title><p>SARS-CoV-2与SARS-CoV的临床表现都是以呼吸系统症状为主，Chen等在调查中发现，SARS-CoV-2的主要临床表现为发热(92.8%)、咳嗽(69.8%)、呼吸困难(34.5%)、肌痛(27.7%)、头痛(7.2%)和腹泻(6.1%)等 [<xref ref-type="bibr" rid="hanspub.38480-ref10">10</xref>]。SARS-CoV患者在感染不同阶段表现不同，感染初期主要出现发烧、干咳、肌肉酸痛、全身乏力，随病情进展发生低氧血症和呼吸困难，甚至出现急性呼吸窘迫综合征(ARDS)、感染性休克等 [<xref ref-type="bibr" rid="hanspub.38480-ref7">7</xref>]。因此，二者的临床表现基本相似，单从临床表现无法区分，疾病进展中的一些差异待进一步证实。</p></sec><sec id="s9"><title>5. 影像学表现</title><p>钟南山团队在840名已确诊SARS-CoV-2且行胸部CT检查的患者中发现，最主要的表现为肺炎(76.4%)，主要表现形式是肺部磨玻璃影(50.0%)和双侧多发斑片影(46.0%) [<xref ref-type="bibr" rid="hanspub.38480-ref4">4</xref>]。赵等在28例新型冠状病毒肺炎患者的临床特征分析中发现，胸部CT主要表现为磨玻璃影21例(75.0%)，边缘模糊18例(64.3%)，斑点、斑片影17例(60.7%)，部分肺纹理增粗、紊乱7例(25%)，可见条索影7例(25%)，局部支气管扩张2例(7.1%)，淋巴结增多、增粗血管影、结节影，无壁透亮区各1例(3.6%) [<xref ref-type="bibr" rid="hanspub.38480-ref11">11</xref>]。M&#252;ller等对12名2003年SARS-CoV感染患者的回顾性研究中发现，SARS-CoV患者的胸部CT影像学表现主要为单侧或双侧毛玻璃影或单侧或双侧的局限性病灶 [<xref ref-type="bibr" rid="hanspub.38480-ref12">12</xref>]。Nestor等在研究中同样发现，SARS-CoV患者主要表现为双侧磨玻璃影，且部分患者出现带状和网状结构伴有轻度牵拉行支气管扩张 [<xref ref-type="bibr" rid="hanspub.38480-ref13">13</xref>]。目前来看，SARS-CoV-2与SARS-CoV的影像学表现大致相似。但由于疾病进展，在不同疾病阶段的影像学表现各异，目前仍需对当前SARS-CoV-2患者不同阶段的影像学表现做进一步研究。</p></sec><sec id="s10"><title>6. 实验室检查</title><p>最新研究数据表明，82.1%的患者淋巴细胞减少，60.7%的患者C反应蛋白水平(CRP)升高，36.2%的患者血小板减少，部分患者出现丙氨酸氨基转移酶、天冬氨酸氨基转移酶、肌酸激酶和D-二聚体水平升高，并且重症患者中以上指标变化更为明显 [<xref ref-type="bibr" rid="hanspub.38480-ref4">4</xref>]。Lee等对138名SARS患者的回顾性分析中发现，淋巴细胞减少症(占69.6%)，血小板减少症(占44.8%)以及乳酸脱氢酶和肌酸激酶水平升高(分别为71.0%和32.1%)，并且在住院期间，许多患者不同程度的发生了低钙、低钾、低镁、低磷等电解质紊乱现象 [<xref ref-type="bibr" rid="hanspub.38480-ref14">14</xref>]。综上，SARS-CoV-2与SARS-CoV的实验学检查中都存在淋巴细胞和血小板减少现象，这是否可证明二者的相关性有待进一步核实。</p></sec><sec id="s11"><title>7. 诊断</title><p>跟据目前最新《新型冠状病毒感染的肺炎诊疗方案(试行第八版)》诊断标准：对疑似病例的诊断需结合流行病学史(疫区相关接触史)和临床表现(发热或存在呼吸道症状；具有上述新冠肺炎影像学和实验室检查特征)。对确诊病例的诊断为在疑似病例基础上存在实时荧光RT-PCR检测新型冠状病毒核酸阳性或病毒基因测序与已知的新型冠状病毒高度同源 [<xref ref-type="bibr" rid="hanspub.38480-ref5">5</xref>]。</p></sec><sec id="s12"><title>8. SARS-CoV-2潜在治疗方案</title><sec id="s12_1"><title>8.1. 抗病毒治疗</title><p>用α-干扰素、洛匹那韦/利托那韦、利巴韦林(建议与干扰素或洛匹那韦/利托那韦联合应用)、磷酸氯喹、阿比多尔治疗有效，同时避免盲目使用抗生素治疗 [<xref ref-type="bibr" rid="hanspub.38480-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.38480-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.38480-ref16">16</xref>]。美国从1例治愈病例中发现，瑞德西韦可能对新型肺炎有一定的治疗效果，同时也指出，瑞德西韦的对新型冠状病毒肺炎的治疗有效性和安全性需要进一步的研究 [<xref ref-type="bibr" rid="hanspub.38480-ref17">17</xref>]。同时，《新型冠状病毒感染的肺炎诊疗方案(试行第八版)》删除了单独使用洛匹那韦/利托那韦的方案，也不推荐使用羟氯喹或联合使用阿奇霉素的方案。</p></sec><sec id="s12_2"><title>8.2. 康复患者血浆置换</title><p>在一项Meta分析研究中，对血浆置换治疗病毒性肺炎的临床疗效的评估中发现，利用幸存者恢复期血浆治疗后，患者死亡率较前下降且具有统计学意义(OR：0.25；95%置信区间：0.14~0.45，P = 0.000) [<xref ref-type="bibr" rid="hanspub.38480-ref18">18</xref>]。杨等 [<xref ref-type="bibr" rid="hanspub.38480-ref19">19</xref>] 提出病毒感染康复者体内会产生抗SARS-CoV-2多克隆抗体，对SARS-CoV-2病原体具有免疫抵抗作用。血浆置换治疗目前只处于临床实验阶段，具体效果有待证实。</p></sec><sec id="s12_3"><title>8.3. 中医治疗</title><p>中医“治未病”思想已在甲型H1N1流行性感冒、人禽流行性感冒、SARS等多种传染病的防治中发挥了重要作用，《新型冠状病毒感染的肺炎诊疗方案(试行第五版)》中对SARS-CoV-2做出了明确分期，且有指定的对应治疗方案 [<xref ref-type="bibr" rid="hanspub.38480-ref20">20</xref>]。在目前无特效药治疗情景下，中西结合治疗可能成为当前疫情的关键治疗措施。</p><p>一般对症治疗及重症患者呼吸、循环支持(ECMO)等治疗措施在此不一一阐述，但目前仍未发现对SARS-CoV-2特效治疗措施，因此，我们仍需加强临床研究，总结出最优治疗方案。</p></sec></sec><sec id="s13"><title>9. 总结与展望</title><p>SARS-CoV-2是SARS-CoV的一对姊妹病毒，具有高度的同源性。两者在流行病学、病原学、临床表现、实验室及影响学检查方面存在一定的相似性，但也有一定的差异。目前《我国新型冠状病毒肺炎诊疗方案》仍在持续更新中，全球出现感染病例的国家也在积极探索最新的治疗方案。相信在全球的互相协作以及国内外基础–临床的紧密联系下，最终会再次取得疫情的胜利。</p></sec><sec id="s14"><title>利益冲突</title><p>所有作者均声明不存在利益冲突。</p></sec><sec id="s15"><title>文章引用</title><p>陈 超,魏玉娇,周宏稷,张 浩,张 超,许丰强,马瑞霞,安 毅. 新型冠状病毒(SARS-CoV-2)与严重急性呼吸综合征冠状病毒(SARS-CoV)研究对比The Comparison of SARS-CoV-2 and SARS-CoV[J]. 临床医学进展, 2020, 10(11): 2439-2443. https://doi.org/10.12677/ACM.2020.1011368</p></sec><sec id="s16"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38480-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Hu, B., Zeng, L.-P., Yang, X.-L., et al. (2017) Discovery of a Rich Gene Pool of bat SARS-Related Coronaviruses provides New Insights into the Origin of SARS Coronavirus. PLOS Pathogens, 13, e1006698.  
&lt;br&gt;https://doi.org/10.1371/journal.ppat.1006698</mixed-citation></ref><ref id="hanspub.38480-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, P., Yang, X.L., Wang, X.G., et al. (2020) A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin. Nature, 579, 270-273.</mixed-citation></ref><ref id="hanspub.38480-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">华南农业大学. 华南农业大学发现穿山甲为新型冠状病毒潜在中间宿主[EB/OL].  
&lt;br&gt;https://www.scau.edu.cn/, 2020-02-13.</mixed-citation></ref><ref id="hanspub.38480-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Guan, W.J., Ni, Z.Y., Hu, Y., et al. (2020) Clinical Characteristics of 2019 Novel Coronavirus Infection in China. The New England Journal of Medicine, 382, 1708-1720.</mixed-citation></ref><ref id="hanspub.38480-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">中华人民共和国国家卫生健康委员会 . 新型冠状病毒感染的肺炎诊疗方案(试行第八版) [EB/OL].  
http://www.nhc.gov.cn/yzygj/s7652m/202008/475d0199d34c4cac840eb7998fad444f.shtml</mixed-citation></ref><ref id="hanspub.38480-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Lau, S.K., Woo, P.C., Li, K.S., Huang, Y., Tsoi, H.W., Wong, B.H., Wong, S.S., Leung, S.Y., Chan, K.H. and Yuen, K.Y. (2005) Severe Acute Respiratory Syndrome Coronavirus-Like Virus in Chinese Horseshoe Bats. Proceedings of the National Academy of Sciences of the United States of America, 102, 14040-14045.  
&lt;br&gt;https://doi.org/10.1073/pnas.0506735102</mixed-citation></ref><ref id="hanspub.38480-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Hui, D.S.C. and Zumla, A. (2019) Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features. Infectious Disease Clinics of North America, 33, 869-889. &lt;br&gt;https://doi.org/10.1016/j.idc.2019.07.001</mixed-citation></ref><ref id="hanspub.38480-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">van Boheemen, S., de Graaf, M., Lauber, C., et al. (2012) Genomic Characterization of a Newly Discovered Coronavirus Associated with Acute Respiratory Distress Syndrome in Humans. MBio, 3, e00473-12.  
&lt;br&gt;https://doi.org/10.1128/mBio.00473-12</mixed-citation></ref><ref id="hanspub.38480-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Lu, R., Zhao, X., Li, J., et al. (2020) Genomic Characterisation and Epidemiology of 2019 Novel Coronavirus: Implications for Virus Origins and Receptor Binding. Lancet, 395, 565-574.</mixed-citation></ref><ref id="hanspub.38480-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., et al. (2020) Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study. The Lancet, 395, 507-513.</mixed-citation></ref><ref id="hanspub.38480-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">赵蕊, 梁运光, 林艳荣, 等. 新型冠状病毒肺炎患者28例的临床特征分析[J]. 中华传染病杂志, 2020(38): E006.</mixed-citation></ref><ref id="hanspub.38480-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Müller, N.L., Ooi, G.C., Khong, P.L. and Nicolaou, S. (2003) Severe Acute Respiratory Syndrome: Radiographic and CT Findings. American Journal of Roentgenology, 181, 3-8. &lt;br&gt;https://doi.org/10.2214/ajr.181.1.1810003</mixed-citation></ref><ref id="hanspub.38480-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Müller, N.L., Ooi, G.C., Khong, P.L., Zhou, L.J., Tsang, K.W.T. and Nicolaou, S. (2004) High-Resolution CT Findings of Severe Acute Respiratory Syndrome at Presentation and after Admission. American Journal of Roentgenology, 182, 39-44.</mixed-citation></ref><ref id="hanspub.38480-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Lee, N., Hui, D., Wu, A., et al. (2003) A Major Outbreak of Severe Acute Respiratory Syndrome in Hong Kong. The New England Journal of Medicine, 348, 1986-1994. &lt;br&gt;https://doi.org/10.1056/NEJMoa030685</mixed-citation></ref><ref id="hanspub.38480-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Li, H., Wang, Y.M., Xu, J.Y. and Cao, B. (2020) Potential antiviral therapeutics for 2019 Novel Coronavirus. Zhonghua Jie He He Hu Xi Za Zhi, 43, 170-172. (In Chinese)</mixed-citation></ref><ref id="hanspub.38480-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., et al. (2020) Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-nCoV) in Vitro. Cell Research, 30, 269-271.   
&lt;br&gt;https://doi.org/10.1038/s41422-020-0282-0</mixed-citation></ref><ref id="hanspub.38480-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Holshue, M.L., DeBolt, C., Lindquist, S., et al. (2020) First Case of 2019 Novel Coronavirus in the United States. The New England Journal of Medicine, 382, 929-936. &lt;br&gt;https://doi.org/10.1056/NEJMoa2001191</mixed-citation></ref><ref id="hanspub.38480-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Mair-Jenkins, J., Saavedra-Campos, M., Baillie, J.K., et al. (2015) The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-Analysis. The Journal of Infectious Diseases, 211, 80-90.  
&lt;br&gt;https://doi.org/10.1093/infdis/jiu396</mixed-citation></ref><ref id="hanspub.38480-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">杨晓明, 侯继峰. 康复期血浆应用于急性病毒性传染病现状及其治疗新型冠状病毒肺炎前景[J/OL]. 中国生物制品学杂志, 1-5. &lt;br&gt;https://doi.org/10.13200/j.cnki.cjb.002999</mixed-citation></ref><ref id="hanspub.38480-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">国家卫生健康委员会. 关于印发新型冠状病毒感染的肺炎诊疗方案(试行第5版)的通知[EB/OL].  
http://www.nhc.gov.cn/yzygj/s7653p/202002/3b09b894ac9b4204a79db5b8912d4440.shtml, 2020-02-05.</mixed-citation></ref></ref-list></back></article>